4 November 2016
Redx Pharma Plc is pleased to announce that it will present the pre-clinical profile of its reversible Bruton’s tyrosine kinase (BTK) inhibitor at the American Society of Hematology (ASH) Annual Meeting on 5 December 2016 in San Diego, California. The compound, named RXC005 (also known as REDX08608), is a novel, potent and selective, reversible BTK inhibitor that is equipotent against wild-type and mutant C481S BTK. C481 mutant BTK protein is currently estimated to be responsible for around 60% of the observed Ibrutinib resistance in patients with chronic lymphocytic leukaemia.
The Company is progressing studies to prepare the RXC005 program for first-in-human clinical trials. The aim is to commence these trials late 2017.
The Abstract for the presentation is available on the ASH Conference website:
Dr Neil Murray, CEO of Redx, said:
We're delighted to present the compelling pre-clinical profile of our reversible BTK inhibitor RXC005 at the prestigious American Society of Hematology Annual Meeting in December.
RXC005 has the potential to become a potent therapy for chronic lymphocytic leukaemia patients by tackling the growing resistance to Ibrutinib treatment. We aim to initiate first-in-human clinical studies for RXC005 late 2017.